Jonathan M Hazlehurst

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7677251/publications.pdf

Version: 2024-02-01

27 papers 2,762 citations

15 h-index 25 g-index

28 all docs

28 docs citations

times ranked

28

4069 citing authors

#	Article	IF	CITATIONS
1	Metformin maintains intrahepatic triglyceride content through increased hepatic de novo lipogenesis. European Journal of Endocrinology, 2022, 186, 367-377.	1.9	12
2	Ramadan is not associated with increased infection risk in Pakistani and Bangladeshi populations: Findings from controlled interrupted time series analysis of UK primary care data. PLoS ONE, 2022, 17, e0262530.	1.1	2
3	How to manage weight loss in women with obesity and PCOS seeking fertility?. Clinical Endocrinology, 2022, , .	1.2	7
4	Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents. Metabolism Open, 2022, 14, 100177.	1.4	6
5	Markers of adipose tissue hypoxia are elevated in subcutaneous adipose tissue of severely obese patients with obesity hypoventilation syndrome but not in the moderately obese. International Journal of Obesity, 2021, 45, 1618-1622.	1.6	14
6	Diet and physical activity in pregnancy to prevent gestational diabetes: a protocol for an individual participant data (IPD) meta-analysis on the differential effects of interventions with economic evaluation. BMJ Open, 2021, 11, e048119.	0.8	6
7	wEight chanGes, caRdio-mEtabolic risks and morTality in patients with hyperthyroidism (EGRET): a protocol for a CPRD–HES linked cohort study. BMJ Open, 2021, 11, e055219.	0.8	О
8	Prognostic Models for Predicting Remission of Diabetes Following Bariatric Surgery: A Systematic Review and Meta-analysis. Diabetes Care, 2021, 44, 2626-2641.	4.3	19
9	Socioâ€demographic predictors of uptake of a virtual group weight management program during the COVIDâ€19 pandemic. Journal of Human Nutrition and Dietetics, 2021, 34, 480-484.	1.3	5
10	Sodiumâ€glucose cotransporter 2 inhibition does not reduce hepatic steatosis in overweight, insulinâ€resistant patients without type 2 diabetes. JGH Open, 2020, 4, 433-440.	0.7	10
11	Developing Integrated Clinical Pathways for the Management of Clinically Severe Adult Obesity: a Critique of NHS England Policy. Current Obesity Reports, 2020, 9, 530-543.	3.5	35
12	Co-administration of $5\hat{l}_{\pm}$ -reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3316-e3328.	1.8	9
13	Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. Clinical Endocrinology, 2019, 90, 440-448.	1.2	16
14	The Endocrine and Metabolic Characteristics of a Large Bardet-Biedl Syndrome Clinic Population. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1834-1841.	1.8	58
15	Advanced nonâ€alcoholic fatty liver disease and adipose tissue fibrosis in patients with Alström syndrome. Liver International, 2016, 36, 1704-1712.	1.9	23
16	Dual-5î±-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 103-113.	1.8	50
17	Non-alcoholic fatty liver disease and diabetes. Metabolism: Clinical and Experimental, 2016, 65, 1096-1108.	1.5	396
18	Compliance with established guidelines for the radiological reporting of atypical femoral fractures. British Journal of Radiology, 2016, 89, 20150443.	1.0	12

#	Article	lF	CITATIONS
19	Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet, The, 2016, 387, 679-690.	6.3	1,397
20	Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. Journal of Hepatology, 2016, 64, 399-408.	1.8	308
21	SFRP2 Is Associated with Increased Adiposity and VEGF Expression. PLoS ONE, 2016, 11, e0163777.	1.1	27
22	Response to the Letter: "Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man― Journal of Clinical Endocrinology and Metabolism, 2016, 101, L48-L49.	1.8	0
23	Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 33-41.	0.2	41
24	A comparative quality assessment of evidenceâ€based clinical guidelines in endocrinology. Clinical Endocrinology, 2013, 78, 183-190.	1.2	35
25	Glucocorticoids Fail to Cause Insulin Resistance in Human Subcutaneous Adipose Tissue In Vivo. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1631-1640.	1.8	53
26	Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders. European Journal of Endocrinology, 2013, 169, R27-R37.	1.9	80
27	Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort. Annals of the Rheumatic Diseases, 2011, 70, 949-955.	0.5	141